The present invention relates to a .beta.3 adrenergic receptor agonist of
formula I: 1
or a pharmaceutical salt thereof; which is capable of increasing lipolysis
and energy expenditure in cells and, therefore, is useful for treating
Type 2 diabetes and/or obesity.
